Thrombophilias and stroke: diagnosis, treatment, and prognosis.
Fields
Madeline C
MC
Department of Neurology, Stroke Center, The Mount Sinai School of Medicine, New York 10029-6574, USA.
Levine
Steven R
SR
D000925:Anticoagulants / Q000627:therapeutic use; D003541:Cystathionine beta-Synthase / Q000235:genetics / Q000378:metabolism; D005165:Factor V / Q000235:genetics; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006710:Homocysteine / Q000378:metabolism; D006801:Humans; D020138:Hyperhomocysteinemia / Q000235:genetics / Q000378:metabolism; D002546:Ischemic Attack, Transient / Q000235:genetics* / Q000517:prevention & control; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics / Q000378:metabolism; D015539:Platelet Activation / Q000235:genetics; D010974:Platelet Aggregation / Q000235:genetics; D011110:Polymorphism, Genetic; D011379:Prognosis; D018455:Protein S Deficiency / Q000235:genetics; D011516:Prothrombin / Q000235:genetics; D055502:Secondary Prevention; D020521:Stroke / Q000209:etiology* / Q000517:prevention & control; D019851:Thrombophilia / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics* / Q000517:prevention & control; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; C095381:factor V Leiden; D006710:Homocysteine; D014859:Warfarin; D005165:Factor V; D011516:Prothrombin; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D003541:Cystathionine beta-Synthase